News
Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694
Zenith Capital Corp. announced that Zenith Epigenetics Ltd. , a wholly-owned subsidiary of Zenith Capital, has entered into a licensing agreement with Newsoara BioPharma...
Press Releases
Aevi Genomic Medicine Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody
Aevi Genomic Medicine, Inc. announced that it has obtained the right to exercise an exclusive global license for MEDI2338, a Phase 2-ready fully human...
News
Aucta Pharmaceuticals Announces Licensing of Vigabatrin for Oral Solution in China
Aucta Pharmaceuticals, Inc. ,a technology based company focusing on the development and commercialization of Branded Specialty Products, announced that the Company has entered into...
IT & Data Management
Boston Analytical Continues Expansion with Office in Cambridge MA
Boston Analytical, a leading provider of analytical and microbiological testing to the pharmaceutical industry, has opened an office in downtown Cambridge. This expansion comes...
News
Sempre health partners with Blue cross blue shield of Arizona to help members save on Medications
Sempre Health, the leading solution for behavior-based healthcare pricing, announced a partnership with Blue Cross Blue Shield of Arizona (BCBSAZ) that features a new...
Articles
The use of positron emission tomography-computed tomography (PET/CT) to assist preclinical oncology research
Positron emission tomography (PET) is a popular nuclear imaging technique used to gain information about specific molecular biomarkers. It is often combined with other...
Drug Research
FDA Approves Daiichi Sankyos TURALIO pexidartinib for the Treatment of Select Patients with TGCT a Rare and Debilitating Tumor
Daiichi Sankyo Company, Limited announced that the U.S. FDA approved TURALIO™ (pexidartinib) as the first and only treatment for adult patients with symptomatic TGCT...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read